Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer
Status:
Active, not recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of neoadjuvant weekly nab-paclitaxel
followed by Adriamycin, Cyclophosphamide (AC) or Epirubicin, Cyclophosphamide (EC) or
Fluorouracil,Epirubicin,Cyclophosphamide (FEC)compared with neoadjuvant weekly solvent-based
paclitaxel followed by AC or EC or FEC in terms of rate of pathological complete remissions
at surgery.